Pesticides & Agrochemicals · Founded 1994 · www.godrejastec.com · BSE 533138 · NSE ASTEC LIFE · ISIN INE563J01010
No Notes Added Yet
Business
Astec Lifesciences Ltd. is a leading Indian manufacturer of agrochemical active ingredients (AIs), intermediates, and pharmaceutical intermediates. The company primarily operates as a business-to-business (B2B) supplier, serving large domestic and international agrochemical and pharmaceutical companies. Its core business model involves leveraging its expertise in complex chemistries (e.g., organo-phosphorus, triazole, hydrazine chemistry) for custom synthesis and contract manufacturing operations (CMO), alongside producing proprietary active ingredients and intermediates. The company makes money by selling these manufactured products to its clients.
Revenue Mix
Astec Lifesciences primarily operates across three broad areas:
Agrochemical Active Ingredients: Manufacturing finished agrochemical products that are ready for formulation by clients.
Agrochemical Intermediates: Producing chemical compounds used as raw materials in the synthesis of more complex agrochemical active ingredients.
Contract Manufacturing & Custom Synthesis (CMO/CRAMS): Providing specialized manufacturing services to global agrochemical and pharmaceutical companies, often involving proprietary chemistries or exclusive arrangements for specific molecules. While specific revenue percentages are not readily available without external data, the company generally maintains a diversified mix between its proprietary products and growing custom synthesis business.
Industry
The company operates in the global Pesticides & Agrochemicals industry, which is characterized by high R&D intensity, strict regulatory frameworks, and increasing demand driven by population growth and the need for food security. The Indian market is a significant global hub for agrochemical manufacturing due to cost efficiencies and technical expertise. Astec Lifesciences positions itself as a specialized manufacturer, focusing on complex and niche chemistries that require significant technical know-how. It stands as a key supplier of intermediates and active ingredients to larger global players, often competing on technical capabilities, quality, and cost-effectiveness rather than brand in the end-user market. Being a subsidiary of Godrej Agrovet Ltd. provides it with strategic backing and synergies.
MOAT
Technical Expertise & Process Know-how: Specialization in complex and hazardous chemistries (e.g., handling hydrazine hydrate, triazole chemistry) creates high entry barriers and sticky customer relationships.
Backward Integration: Strategic backward integration into key raw materials or intermediates helps control costs, ensure supply security, and improve margins.
Customer Relationships & Trust: Long-standing relationships with large global and domestic agrochemical companies, particularly in contract manufacturing, often involve trust built over years of consistent quality and reliability.
Regulatory Compliance: Adherence to stringent environmental, health, and safety (EHS) standards and obtaining necessary regulatory approvals are critical in the chemical industry and serve as a barrier to new entrants.
Parentage: Being part of the Godrej Group (via Godrej Agrovet) provides financial stability, strong corporate governance, and potential synergistic advantages.
Growth Drivers
Increasing Global Food Demand: Drives demand for crop protection chemicals to enhance agricultural productivity.
Growth in Contract Manufacturing (CMO/CRAMS): Global agrochemical majors are increasingly outsourcing manufacturing to optimize costs and focus on R&D, creating opportunities for specialized players like Astec.
New Product Development & Registration: Successful development and commercialization of new active ingredients and intermediates can open new revenue streams.
Expansion into New Geographies/Markets: Tapping into underserved or growing international markets.
Backward Integration Initiatives: Further integration can improve cost structures and supply chain resilience.
Synergies with Godrej Agrovet: Potential for collaboration and preferred supplier status within the broader Godrej ecosystem.
Risks
Raw Material Price Volatility: Fluctuations in the prices of key chemical raw materials can impact production costs and margins.
Regulatory Risks: Changes in environmental regulations, pesticide registration norms, or import/export policies in India or client countries can affect operations and product viability.
Weather Dependency: Demand for agrochemicals is directly linked to agricultural output, which is highly dependent on weather conditions and monsoon patterns.
Intense Competition: Competition from domestic and international players, particularly from China, can put pressure on pricing and market share.
Forex Fluctuations: As a significant exporter and importer, the company is exposed to currency exchange rate volatility.
R&D Success Rate: The success of new product development is crucial, and R&D failures can lead to sunk costs without returns.
Client Concentration: Potential reliance on a few large clients for custom synthesis orders could pose a risk if those relationships falter.
Management & Ownership
Astec Lifesciences is promoted by the Godrej Group, a venerable Indian conglomerate, through its subsidiary Godrej Agrovet Ltd. Godrej Agrovet holds a significant majority stake, ensuring strong promoter backing and strategic alignment. The management team is generally professional and benefits from the strong corporate governance standards associated with the Godrej Group. The operational management is typically composed of experienced professionals from the chemical and agrochemical industries, responsible for driving technical expertise and operational efficiency.
Outlook
Astec Lifesciences operates in a fundamentally growing industry driven by global food demand and the increasing trend of outsourcing in the chemical sector. Its focus on specialized chemistries and contract manufacturing positions it well to capture growth opportunities. The strong backing of the Godrej Group provides stability and potential synergies. However, the company remains susceptible to inherent risks of the chemical industry, including raw material price volatility, stringent and evolving regulatory landscapes, and the vagaries of agricultural cycles. Its ability to continuously innovate, expand its product portfolio, and efficiently manage its cost structure will be key to sustaining growth amidst competitive pressures.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 154 | 69 | 99 | 94 | 120 | 91 | 74 | 125 | 159 | 84 |
| Other Income | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 3 | 1 |
| Total Income | 156 | 70 | 101 | 96 | 120 | 92 | 75 | 126 | 161 | 84 |
| Total Expenditure | 141 | 116 | 118 | 100 | 114 | 102 | 80 | 121 | 149 | 84 |
| Operating Profit | 15 | -45 | -18 | -4 | 6 | -10 | -6 | 5 | 12 | 0 |
| Interest | 7 | 7 | 9 | 10 | 10 | 11 | 8 | 7 | 8 | 8 |
| Depreciation | 9 | 9 | 11 | 11 | 12 | 11 | 10 | 11 | 12 | 11 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 |
| Profit Before Tax | -1 | -62 | -39 | -25 | -16 | -33 | -24 | -16 | -8 | -19 |
| Provision for Tax | 0 | -22 | 0 | 15 | 0 | 0 | 0 | 0 | -0 | -0 |
| Profit After Tax | -1 | -40 | -39 | -40 | -16 | -33 | -24 | -16 | -8 | -19 |
| Adjustments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Profit After Adjustments | -1 | -40 | -39 | -40 | -16 | -33 | -24 | -16 | -8 | -19 |
| Adjusted Earnings Per Share | -0.5 | -20.1 | -19.5 | -20.4 | -8.1 | -16.7 | -11 | -7 | -3.5 | -8.4 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 247 | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 458 | 381 | 448 | 442 |
| Other Income | 7 | 3 | 8 | 11 | 12 | 8 | 10 | 13 | 6 | 6 | 5 | 6 |
| Total Income | 254 | 302 | 376 | 442 | 535 | 563 | 687 | 641 | 464 | 387 | 453 | 446 |
| Total Expenditure | 215 | 236 | 299 | 354 | 437 | 443 | 522 | 552 | 464 | 448 | 453 | 434 |
| Operating Profit | 39 | 65 | 77 | 88 | 97 | 119 | 165 | 89 | -0 | -61 | 1 | 11 |
| Interest | 13 | 12 | 11 | 12 | 13 | 5 | 9 | 21 | 25 | 37 | 35 | 31 |
| Depreciation | 10 | 14 | 15 | 19 | 23 | 26 | 34 | 34 | 36 | 44 | 45 | 44 |
| Exceptional Income / Expenses | -3 | -11 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -2 |
| Profit Before Tax | 12 | 29 | 56 | 56 | 61 | 89 | 121 | 35 | -62 | -141 | -81 | -67 |
| Provision for Tax | 7 | 10 | 21 | 20 | 14 | 24 | 31 | 9 | -15 | -6 | -0 | 0 |
| Profit After Tax | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | -47 | -135 | -81 | -67 |
| Adjustments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 |
| Profit After Adjustments | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | -47 | -135 | -81 | -67 |
| Adjusted Earnings Per Share | 2.5 | 9.7 | 17.7 | 18.1 | 24.1 | 33 | 45.5 | 12.9 | -23.8 | -68.2 | -36.3 | -29.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 18% | -11% | -4% | 6% |
| Operating Profit CAGR | 0% | -78% | -62% | -31% |
| PAT CAGR | 0% | NAN% | NAN% | NAN% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -1% | -18% | -11% | 4% |
| ROE Average | -26% | -27% | -10% | 5% |
| ROCE Average | -6% | -8% | 1% | 11% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 118 | 138 | 170 | 202 | 247 | 309 | 396 | 419 | 369 | 235 | 391 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 8 | 0 | 0 | 0 | 0 | 40 | 0 | 11 | 199 | 280 | 50 |
| Other Non-Current Liabilities | -2 | 1 | 5 | 9 | 6 | 6 | 38 | 23 | 9 | 6 | 1 |
| Total Current Liabilities | 203 | 194 | 238 | 249 | 318 | 322 | 491 | 526 | 397 | 366 | 500 |
| Total Liabilities | 328 | 334 | 413 | 461 | 572 | 678 | 925 | 979 | 975 | 887 | 942 |
| Fixed Assets | 95 | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 386 | 499 | 459 |
| Other Non-Current Assets | 42 | 32 | 66 | 46 | 46 | 134 | 70 | 162 | 191 | 47 | 40 |
| Total Current Assets | 191 | 198 | 232 | 248 | 332 | 330 | 516 | 499 | 398 | 341 | 443 |
| Total Assets | 328 | 334 | 413 | 461 | 572 | 678 | 925 | 979 | 975 | 887 | 942 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 2 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Cash Flow from Operating Activities | -13 | 19 | 65 | 15 | 168 | -8 | 24 | 75 | 10 | -8 | -81 |
| Cash Flow from Investing Activities | -16 | -18 | -49 | -52 | -74 | -73 | -104 | -113 | -135 | -15 | -4 |
| Cash Flow from Financing Activities | 31 | -1 | -18 | 37 | -95 | 81 | 80 | 38 | 125 | 24 | 94 |
| Net Cash Inflow / Outflow | 2 | 1 | -3 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 9 |
| Closing Cash & Cash Equivalent | 2 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 10 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 2.53 | 9.73 | 17.74 | 18.14 | 24.1 | 32.97 | 45.52 | 12.95 | -23.76 | -68.21 | -36.31 |
| CEPS(Rs) | 7.89 | 16.72 | 25.28 | 27.98 | 35.86 | 45.98 | 62.94 | 30 | -5.39 | -46.06 | -16.14 |
| DPS(Rs) | 0 | 1.49 | 1.49 | 1.49 | 1.49 | 1.49 | 1.49 | 1.49 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 59.85 | 69.85 | 85.8 | 102.42 | 124.75 | 156.49 | 200.71 | 212.17 | 186.77 | 118.77 | 175.24 |
| Core EBITDA Margin(%) | 12.78 | 19.91 | 18.55 | 17.67 | 16.21 | 19.95 | 22.66 | 12.08 | -1.29 | -17 | -1.01 |
| EBIT Margin(%) | 10.22 | 13.08 | 17.9 | 15.78 | 14.07 | 16.79 | 19.15 | 8.82 | -7.95 | -26.78 | -10.37 |
| Pre Tax Margin(%) | 5.03 | 9.17 | 15.02 | 12.92 | 11.67 | 15.94 | 17.82 | 5.54 | -13.45 | -36.21 | -18.07 |
| PAT Margin (%) | 2.05 | 6.12 | 9.45 | 8.27 | 9.04 | 11.64 | 13.22 | 4.05 | -10.21 | -34.6 | -18.05 |
| Cash Profit Margin (%) | 6.26 | 10.49 | 13.41 | 12.74 | 13.45 | 16.24 | 18.28 | 9.39 | -2.32 | -23.37 | -8.02 |
| ROA(%) | 1.47 | 5.8 | 9.38 | 8.18 | 9.2 | 10.42 | 11.21 | 2.69 | -4.8 | -14.47 | -8.84 |
| ROE(%) | 4.01 | 15.07 | 22.9 | 19.31 | 21.24 | 23.46 | 25.5 | 6.28 | -11.9 | -44.64 | -25.88 |
| ROCE(%) | 10.65 | 16.08 | 23.75 | 20.31 | 20.44 | 22.29 | 22.21 | 7.75 | -4.5 | -12.62 | -5.71 |
| Receivable days | 136.14 | 111.38 | 115.06 | 103.32 | 98.14 | 113.66 | 123.7 | 123.89 | 128.71 | 148.32 | 160.92 |
| Inventory Days | 105.79 | 79.66 | 70.88 | 72.27 | 74.31 | 74.22 | 78.67 | 139.3 | 194.99 | 166.7 | 121.29 |
| Payable days | 176.72 | 126.85 | 121.9 | 106.55 | 143.21 | 176.37 | 150.04 | 166.93 | 152.31 | 105.03 | 103.52 |
| PER(x) | 76.38 | 61.59 | 32.54 | 29.47 | 16.47 | 30.12 | 38.22 | 106.02 | 0 | 0 | 0 |
| Price/Book(x) | 3.23 | 8.58 | 6.73 | 5.22 | 3.18 | 6.35 | 8.67 | 6.47 | 5.65 | 5.64 | 3.08 |
| Dividend Yield(%) | 0 | 0.25 | 0.26 | 0.28 | 0.38 | 0.15 | 0.09 | 0.11 | 0 | 0 | 0 |
| EV/Net Sales(x) | 2.03 | 4.35 | 3.43 | 2.85 | 1.68 | 3.87 | 5.49 | 4.85 | 5.62 | 4.92 | 3.66 |
| EV/Core EBITDA(x) | 12.9 | 19.92 | 16.37 | 14.01 | 9.06 | 17.95 | 22.56 | 34.14 | -9579.67 | -30.96 | 3007.12 |
| Net Sales Growth(%) | -7.45 | 20.92 | 23.07 | 17.23 | 21.28 | 6.17 | 21.93 | -7.15 | -27.06 | -16.78 | 17.53 |
| EBIT Growth(%) | -0.75 | 62.42 | 61.97 | 2.87 | 8.3 | 26.88 | 38.76 | -57.24 | -165.61 | -185.56 | 55.44 |
| PAT Growth(%) | -65.73 | 278.55 | 82.69 | 2.08 | 32.89 | 36.91 | 38.13 | -71.53 | -283.21 | -187.29 | 39.96 |
| EPS Growth(%) | -66.39 | 283.78 | 82.44 | 2.26 | 32.84 | 36.78 | 38.07 | -71.56 | -283.54 | -187.11 | 46.76 |
| Debt/Equity(x) | 1.08 | 0.92 | 0.74 | 0.87 | 0.4 | 0.61 | 0.71 | 0.81 | 1.34 | 2.36 | 1.15 |
| Current Ratio(x) | 0.94 | 1.02 | 0.97 | 1 | 1.04 | 1.03 | 1.05 | 0.95 | 1 | 0.93 | 0.89 |
| Quick Ratio(x) | 0.59 | 0.69 | 0.64 | 0.63 | 0.66 | 0.7 | 0.67 | 0.39 | 0.51 | 0.5 | 0.61 |
| Interest Cover(x) | 1.97 | 3.35 | 6.23 | 5.52 | 5.87 | 19.75 | 14.37 | 2.69 | -1.45 | -2.84 | -1.35 |
| Total Debt/Mcap(x) | 0.33 | 0.11 | 0.11 | 0.17 | 0.13 | 0.1 | 0.08 | 0.13 | 0.24 | 0.42 | 0.37 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.75 | 66.75 | 66.75 | 66.75 | 70.87 | 70.87 | 72.42 | 71.97 | 71.97 | 71.96 |
| FII | 1.25 | 1.03 | 0.53 | 1.2 | 0.25 | 0.02 | 0 | 0.04 | 0.02 | 0.01 |
| DII | 7.88 | 3.38 | 4.51 | 4.63 | 4.34 | 4.26 | 4.01 | 3.17 | 3.34 | 3.33 |
| Public | 24.11 | 28.84 | 28.21 | 27.42 | 24.54 | 24.84 | 23.57 | 24.82 | 24.67 | 24.69 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.31 | 1.31 | 1.31 | 1.31 | 1.39 | 1.39 | 1.61 | 1.6 | 1.6 | 1.6 |
| FII | 0.02 | 0.02 | 0.01 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.15 | 0.07 | 0.09 | 0.09 | 0.09 | 0.08 | 0.09 | 0.07 | 0.07 | 0.07 |
| Public | 0.47 | 0.57 | 0.55 | 0.54 | 0.48 | 0.49 | 0.53 | 0.55 | 0.55 | 0.55 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.96 | 1.96 | 1.96 | 1.96 | 1.96 | 1.96 | 2.23 | 2.23 | 2.23 | 2.23 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +18% | -11% | -4% | +6% |
| Operating Profit CAGR | — | -78% | -62% | -31% |
| PAT CAGR | — | 0% | 0% | 0% |
| Share Price CAGR | -1% | -18% | -11% | +4% |
| ROE Average | -26% | -27% | -10% | +5% |
| ROCE Average | -6% | -8% | +1% | +11% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.75 | 66.75 | 66.75 | 66.75 | 70.87 | 70.87 | 72.42 | 71.97 | 71.97 | 71.96 |
| FII | 1.25 | 1.03 | 0.53 | 1.2 | 0.25 | 0.02 | 0 | 0.04 | 0.02 | 0.01 |
| DII | 7.88 | 3.38 | 4.51 | 4.63 | 4.34 | 4.26 | 4.01 | 3.17 | 3.34 | 3.33 |
| Public | 24.11 | 28.84 | 28.21 | 27.42 | 24.54 | 24.84 | 23.57 | 24.82 | 24.67 | 24.69 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.31 | 1.31 | 1.31 | 1.31 | 1.39 | 1.39 | 1.61 | 1.6 | 1.6 | 1.6 |
| FII | 0.02 | 0.02 | 0.01 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.15 | 0.07 | 0.09 | 0.09 | 0.09 | 0.08 | 0.09 | 0.07 | 0.07 | 0.07 |
| Public | 0.47 | 0.57 | 0.55 | 0.54 | 0.48 | 0.49 | 0.53 | 0.55 | 0.55 | 0.55 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.96 | 1.96 | 1.96 | 1.96 | 1.96 | 1.96 | 2.23 | 2.23 | 2.23 | 2.23 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.